SCHEMBL2783641

SCHEMBL2783641

CCN1CCN(c2cccc(C(F)(F)F)c2O)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.43
GRM2 Q14416 1/20 0.43
CHRNA7 P36544 1/20 0.42
CHRM4 P08173 3/20 0.42
CHRM1 P11229 3/20 0.42
CHRM5 P08912 2/20 0.42
CHRM3 P20309 2/20 0.42
CHRM2 P08172 1/20 0.42
CNR2 P34972 1/20 0.41
DRD2 P14416 4/20 0.41
HTR6 P50406 2/20 0.41
HTR1A P08908 1/20 0.41
HTR2A P28223 1/20 0.41
HTR7 P34969 1/20 0.41
DRD3 P35462 3/20 0.40
AKR1C3 P42330 1/20 0.40
KDM2B Q8NHM5 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
LMNA P02545 1/20 0.40
NOTUM Q6P988 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2783765 0.89 DRD2 (0.52) DRD4GRM2DRD2HTR6HTR1A
SCHEMBL31096308 0.84 DRD4 (0.55) DRD4GRM2CHRNA7CNR2DRD2
SCHEMBL2780572 0.84 CHRNA7 (0.44) DRD4GRM2CHRNA7CHRM4CHRM1
SCHEMBL2782349 0.84 NOTUM (0.48) DRD4GRM2CHRNA7CHRM4CHRM1
SCHEMBL2783130 0.82 HTR1A (0.42) DRD4GRM2DRD2HTR6HTR1A
SCHEMBL2782933 0.82 DRD2 (0.51) DRD4GRM2CHRNA7CHRM4CHRM1
SCHEMBL2784880 0.82 GAA (0.44) DRD4GRM2CHRNA7CHRM4CHRM1
SCHEMBL2783285 0.82 HTR1A (0.40) DRD4GRM2DRD2HTR6HTR1A
SCHEMBL2784944 0.80 ALDH1A1 (0.50) CHRNA7DRD2DRD3KDM2B
SCHEMBL2782742 0.79 KDM2B (0.47) DRD4CHRNA7DRD2HTR1ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256163-A1 DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2010-10-07 US claimed
EP-2204363-A1 New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) 2010-07-07 EP claimed
US-20070149542-A1 DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2007-06-28 US claimed
US-8314126-B2 Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2012-11-20 US disclosed
US-20100256163-A1 DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2010-10-07 US disclosed
US-7763639-B2 Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2010-07-27 US disclosed
EP-2204363-A1 New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) 2010-07-07 EP disclosed
US-20070149542-A1 DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256163-A1 DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION DRD2, DRD4, DRD1 DRD4 2/4885GRM2 78/4885CHRNA7 201/4885
US-20070149542-A1 DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION DRD2, DRD4, DRD1 DRD4 2/4885GRM2 84/4885CHRNA7 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.